



April 8, 2015

Amarin and Non-Profit, Walk with a Doc Partner to Expand National Health Awareness Efforts

BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 04/08/15 -- Amarin Corporation, plc (NASDAQ: AMRN) and Walk with a Doc, a national nonprofit organization, today announced a 2015 partnership to expand the reach of their national health awareness efforts.

Walk with a Doc is a free participation, year-round walking program held in communities across the United States and abroad. The program is dedicated to encouraging healthy physical activity in people of all ages with the goal of reversing the consequences of a sedentary lifestyle and improving health and well-being. Each walk is hosted by local physicians in public spaces and everyone is welcome.

The education that *Walk with a Doc* does in local communities on the issues of lack of diet and exercise fits well with Amarin's *Lower My Trigs™* campaign. *Lower My Trigs™* is a national awareness initiative that features Rick Harrison, Star of the hit television show "Pawn Stars"® and encourages those with very high triglycerides to exercise, diet and learn more about the health issues associated with this condition.

Dr. David Sabgir, cardiologist and founder of Walk with a Doc, stated, "Amarin's work to educate patients about very high triglycerides positions them as a great partner for our programs. Through this collaboration, we are working together to increase awareness of the importance of lipid management, diet and exercise to help improve the overall health of our local communities."

"This partnership with Walk with a Doc meaningfully complements the *Lower My Trigs™* campaign," said John Thero, President and Chief Executive Officer of Amarin. "We saw the initiative Walk with a Doc was taking in local communities across the country and we wanted to support that effort and get involved. Regardless of medical condition, proper diet and exercise is always paramount in achieving quality outcomes. We're pleased to be a part of this exciting program that has the potential to positively impact so many people."

To learn more about the *Lower My Trigs™* campaign please visit www.lowermytrigs.com; to find walks in your area visit www.walkwithadoc.org.

About Vascepa® (icosapent ethyl) capsules

Vascepa® (icosapent ethyl) capsules, known in scientific literature as AMR101, is a highly-pure EPA omega-3 prescription product in a 1 gram capsule.

Indications and Usage

- Vascepa (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.
- The effect of Vascepa on the risk for pancreatitis and cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined.

Important Safety Information for Vascepa

- Vascepa is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to Vascepa or any of its components and should be used with caution in patients with known hypersensitivity to fish and/or shellfish.
- The most common reported adverse reaction (incidence $> 2\%$ and greater than placebo) was arthralgia (2.3% for Vascepa, 1.0% for placebo). There was no reported adverse reaction $> 3\%$ and greater than placebo.

FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and

the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes commitment to an ongoing outcomes study. Vascepa[®] (icosapent ethyl), Amarin's first FDA approved product, is a highly-pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

Amarin contact information:

Michael Farrell

Investor Relations and Corporate Communications

Amarin Corporation

In U.S.: +1 (908) 719-1315

investor.relations@amarincorp.com

Graham Morrell

Trout Group

U.S.: +1 (646) 378-2954

gmorrell@troutgroup.com

Source: Amarin Corp. Plc

News Provided by Acquire Media